Editor’s note Mathematician John Nash, known as the real-life figure portrayed in the Academy Award-winning film ‘A Beautiful ...

The US Food and Drug Administration (FDA) has approved Teva’s Weltruza, the first long-acting olanzapine injection that can ...

The FDA has cleared Motivista, the first prescription digital therapeutic indicated to treat negative symptoms of schizophrenia as an adjunct to antipsychotic therapy.

Compared with placebo, the mean difference in change in PANSS total score from baseline to week 8 was -9.75 points (CI: -13.60, -5.89) , -11.27 points (CI: -15.01, -7.53), and -9.76 points (CI: -13.50 ...

FDA approves Teva's Weltruza, the first once-monthly subcutaneous olanzapine LAI for adult schizophrenia. Read what it means ...

Teva wins FDA approval for Weltruza, the first once-monthly subcutaneous olanzapine injection for adults with schizophrenia, ...

Teva’s Weltruza was “developed with the patient in mind from day one,” says Chris Fox, Executive VP, as the company advances ...

Teva said it is debuting the drug to overcome adherence issues with an oral counterpart and improve symptom outcomes.

Tortugas Neuroscience’s schizophrenia drug from Hansoh Pharma has proven its worth in a phase 2b study, validating the ...

Each obuprazine dose group demonstrated statistically significant and clinically meaningful improvements versus placebo on ...

Teva Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved WELTRUZA? (olanzapine) for extended-release injectable suspension, a new, once-monthly, subcutaneous ...

Weltruza follows the 2023 approval of Uzedy, extending Teva's partnership with France's Medincell as it seeks to build new ...